共 158 条
[1]
Siegel RL(2023)Cancer statistics, 2023 CA Cancer J Clin 73 17-48
[2]
Miller KD(2020)Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy Hematol Am Soc Hematol Educ Program 2020 33-40
[3]
Wagle NS(2022)Management of relapsed/refractory chronic lymphocytic leukemia Am J Hematol 97 S11-S18
[4]
Jemal A(2015)Imbruvica (ibrutinib), first-in-class Bruton’s tyrosine kinase inhibitor, receives expanded indications for patients with relapsed chronic lymphocytic leukemia Am Health Drug Benefits. 8 66-69
[5]
Moreno C(2019)Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma Am J Hematol 94 1353-1363
[6]
Woyach JA(2018)Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis Haematologica 103 874-879
[7]
Raedler LA(2019)Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase J Med Chem 62 7923-7940
[8]
Munir T(2023)Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia N Engl J Med 388 319-332
[9]
Brown JR(2022)NCCN Guidelines® insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, Version 3.2022 J Natl Compr Canc Netw 20 622-634
[10]
O’Brien S(2021)Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 32 23-33